The Largest and Longest-Running Event Devoted to Designing Reliable Assays and Safer Molecules, and Setting Industry-Leading Strategies to Ensure the Safety of Follow-On Biologics
The 13th Annual Immunogenicity for Biotherapeutics conference was a tremendous success! We hope that you benefited from its unequaled in-depth analysis of immunogenicity prediction, prevention, modeling and assay design, and state-of-the-art applications for the development of safe follow-on biologics.
Our first-ever staging of the full-day intensive “Immunogenicity University” session was a crowd favorite, with very active and animated discussions and troubleshooting groups working on all the most day-to-day pressing technical challenges in statistical analysis and assay transferability.
We would like to thank all of our attendees, speakers, sponsors, and exhibitors for making the event possible, and particularly to thank our FDA experts: Dr. Susan Kirshner, Dr. Laura Salazar-Fontana, and Dr. Amy Rosenberg.